- Development of matrix metalloproteinase-13 inhibitors – A structure-activity/structure-property relationship study
-
A structure-activity/structure-property relationship study based on the physicochemical as well as in vitro pharmacokinetic properties of a first generation matrix metalloproteinase (MMP)-13 inhibitor (2) was undertaken. After systematic variation of inhi
- Fuerst, Rita,Yong Choi, Jun,Knapinska, Anna M.,Smith, Lyndsay,Cameron, Michael D.,Ruiz, Claudia,Fields, Gregg B.,Roush, William R.
-
p. 4984 - 4995
(2018/09/27)
-
- Photooxygenation of an amino-thienopyridone yields a more potent PTP4A3 inhibitor
-
The phosphatase PTP4A3 is an attractive anticancer target, but knowledge of its exact role in cells remains incomplete. A potent, structurally novel inhibitor of the PTP4A family was obtained by photooxygenation of a less active, electron-rich thienopyrid
- Salamoun, Joseph M.,McQueeney, Kelley E.,Patil, Kalyani,Geib, Steven J.,Sharlow, Elizabeth R.,Lazo, John S.,Wipf, Peter
-
p. 6398 - 6402
(2016/07/16)
-
- Synthesis of new 1-phenylthieno[1,2,4]triazolo[4,3-a]pyrimidin-5(4H)-one derivatives
-
A series of novel 1-phenylthieno[1,2,4]triazolo[4,3-a]pyrimidin-5(4H)-one derivatives 5 and 6 were synthesized by oxidative cyclization of thienopyrimidinonyl hydrazones using iodobenzene diacetate.
- Song, Yang-Heon,Son, Hoon Young
-
p. 597 - 603
(2011/07/07)
-
- Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
-
The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2/su
- -
-
Page/Page column 22
(2008/06/13)
-
- Bicyclic pyridine and pyrimidine p38 kinase inhibitors
-
The present invention discloses compounds corresponding to formula wherein A, R, X, Y, R, R1 and R2 are as defined above, pharmaceutical formulations, methods of making and uses thereof.
- -
-
Page/Page column 18
(2010/01/31)
-